Nektar Therapeutics (NKTR) received a Buy rating and a $35.00 price target from Mizuho Securities analyst Difei Yang today. The company’s shares closed last Monday at $19.89, close to its 52-week low of $15.64.
According to TipRanks.com, Yang is a 2-star analyst with an average return of 0.1% and a 41.1% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Revance Therapeutics, and Akebia Therapeutics.
Currently, the analyst consensus on Nektar Therapeutics is a Moderate Buy with an average price target of $29.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $47.11 and a one-year low of $15.64. Currently, Nektar Therapeutics has an average volume of 2.63M.
Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NKTR in relation to earlier this year. Most recently, in December 2019, Roy Whitfield, a Director at NKTR bought 10,000 shares for a total of $92,400.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments.